a

a

Invasion and migration are crucial steps within the metastatic process, leading to the possibility of the growth of cancer cells in different parts of the body. Blocking these mechanisms could become a new approach in cancer therapy, in addition to drugs that work again cell proliferation.Migrastatics are an anti-metastatic class of agents that role is blocking the invasion phase of the metastatic process, with actin-myosin contractility and actin polymerization as ultimate effectors. To date, such types of drugs have not been introduced to the pharmacotherapy of cancers yet. AKT and ROCK kinases were found to be important elements of metastasis ethiopatogenesis and both became attractive biological targets searching for the first, effective anti-metastatic drugs. In the studies was confirmed, that only simultaneous, complementary inhibition of AKT and ROCK isoforms result in an effective ant-metastatic effect, while selective inhibitors didn’t stop invasions of cancers. The aim of our research was searching for new, potential dual inhibitors of AKT/ROCK kinases, with a well-balanced profile of activity. To date, the most promising drug candidate in searching for the first migrastatic is CCT129254, which is a potent inhibitor of ATK and a moderate inhibitor of ROCK isoforms. We selected CCT129254 as a starting point of our studies and based on it we designed a series of new, potential AKT/ROCK inhibitors. We replaced the heteroaromatic fragment of the structure with various scaffolds able to interact with the Hinge regions of kinases to find the optimal one creating interactions with both AKT and ROCK. In the future, it let to define the best balance of AKT/ROCK inhibitory activities that provide the strongest anti-metastatic properties. In this master thesis, we obtained, the series of six final products with diverse scaffolds addressed to the hinge region of targeting kinases. Their activity against the targeted kinases (AKT-1, AKT-2, AKT-3, and ROCK-1, ROCK-2) will be studied in the future.